Bank Of New York Mellon Corp Impel Pharmaceuticals Inc Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.96 - $4.1 $33,888 - $144,734	35,301 New	35,301 $49.4 Million
Q4 2022 Feb 14, 2023	BUY	$2.59 - $4.0 $91,429 - $141,204	35,301 New	35,301 $132,000
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $1,566 - $2,525	271 Added 0.77%	35,301 $172,000
Q2 2022 Aug 15, 2022	SELL	$5.83 - $10.12 $76,413 - $132,642	-13,107 Reduced 27.23%	35,030 $327,000
Q1 2022 May 11, 2022	SELL	$5.86 - $9.85 $7,975 - $13,405	-1,361 Reduced 2.75%	48,137 $306,000
Q4 2021 Feb 11, 2022	BUY	$8.33 - $12.14 $125,599 - $183,046	15,078 Added 43.81%	49,498 $427,000
Q3 2021 Nov 12, 2021	BUY	$8.38 - $26.13 $288,439 - $899,394	34,420 New	34,420 $419,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.